MENU
KLRS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Kalaris Therapeutics (KLRS) Ownership - Who owns Kalaris Therapeutics?
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
51.62M
P/E Ratio
N/A
Total Cash
100.97M
Projected Growth
N/A
Total Debt
N/A
Revenue
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
5.40
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
KLRS
Capitalization
51.6M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
101M
Total Cash/Share
5.40
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
N/A
ROE
N/A
Book Value
63.9M
P/B Ratio
0.81
Cash Flow
N/A
Earnings
N/A
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
2K
Current Ratio
14.31
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
N/A
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
N/A
Shares Held By Institutions
106M
Shares Outstanding - Current
18.7M
Total Liabilities
39.2M
Total Volume MTD
N/A
Value
1
Gain YTD
557.143
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information